Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


FDA “Safety First” Initiative, Agency’s Requests Draw Doubts From DeLauro

This article was originally published in The Tan Sheet

Executive Summary

FDA is implementing the Safety First initiative to "ensure that significant post-market safety issues are our highest priority," according to acting Center for Drug Evaluation and Research Director Janet Woodcock

Related Content

Elections Reshape FDA Oversight Scene On Capitol Hill
Switch Case Study: GSK Alli Review Shows FDA Data Mining In Context
FDA’s Nonprescription Office Adds Executive Posts To Fulfill “Safety First”
FDA’s 5-Year Plan For User Fees Gives Equal Footing To Post- And Pre-Market
FDA Misses User Fee Goals As Resources Tighten For Reviews, SPAs
Woodcock Stays At CDER: Drug Center’s Gain Is FDA Science Program’s Loss
FDA’s “Dysfunctional” Hiring System May Be Good For Safety Databases
CDER director
Von Eschenbach asks for legislation
CDER seeks director





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts